Market Overview

BCMA-Targeted Immunotherapeutics in: October 2016 R&D and Business Tracker for Bispecific Antibodies - Research and Markets

Share:
DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "BCMA-Targeted Immunotherapeutics in: October 2016 R&D and Business Tracker for Bispecific Antibodies" report to their offering.

BCMA-Targeted Immunotherapeutics in: October 2016 R&D and Business Tracker for Bispecific Antibodies

This pdf report contains information about Bispecific Antibodies released during the month of October 2016. This issue forms part of the subscription service R&D and Business Tracker for Bispecific Antibodies.

Featured presentations of October 2016 include the pipeline of B-Cell Maturation Antigen (BCMA)-targeted immunotherapeutics, the profile of German technology company Pieris Pharmaceuticals and the bispecific technology profile of FIT-Ig from EpiMab.

The October 2016 issue of our R&D and Business Tracker service about Bispecific Antibodies covers;

- T-Cell redirecting bispecific cancer antibodies

- NK cell redirecting bispecific cancer antibodies

- Bispecific immuno-oncology antibodies

- Bispecific tumor antigens targeted cancer antibodies

- Bispecific antibodies for inflammatory & autoimmune diseases

- Bispecific antibodies for cardiometabolic, infectious, neurologic, ophthalmic or pulmonary diseases

The monthly update report about Bispecific Antibodies contains:

R&D and Technology Tracker:

- Pipeline changes

- Regulatory news

- Technology validations

- Manufacturing news

Business Tracker for:

- Company updates

- Collaboration

- Licensing

- Merger & acquisitions

- Financing

Clinical Trial Tracker

Scientific Publication Tracker

Featured Bispecific Technology Profile: FIT-Ig

Featured Company Profile: Pieris Pharmaceuticals

Featured Target or Technology Pipeline: BCMA-Targeted Immunotherapeutics

BCMA-Targeted Immunotherapeutics include:

- Autologous & allogeneic T-Cells

- Bispecific tumor-targeted antibodies & T-cells

- Bispecific T-Cell and NK-Cell redirecting antibodies

- Antibody-Drug Conjugates

Information about the BCMA-Targeted Immunotherapeutics pipeline is provided in a tabular format and fully referenced.

For more information about this report visit http://www.researchandmarkets.com/research/5l63kw/bcmatargeted

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Oncology Drugs

View Comments and Join the Discussion!